Press Releases

View: All Categories General Releases Financial Releases Year: All Years 2009 2008 2007 2006 2005 2004 All Releases Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover Nov 16, 2009 13.4 KB   SEATTLE, Nov. 16, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partner... Read more Oncothyreon reports third quarter 2009 financial results & provides product pipeline update Nov 11, 2009 20.1 KB   SEATTLE, Nov. 11, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the three and nine months ended September 30, 2009 and provided a product pipeline update. Management will hold a conference call today at 4:30 p.m. ET, 1:30 p.m. PT (see below for details). Oncothyreon report... Read more Oncothyreon announces webcast of third quarter 2009 financial results conference call Nov 2, 2009 9.5 KB   SEATTLE, Nov. 2, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its third quarter 2009 financial results on Wednesday, November 11, 2009 after market c... Read more Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors Oct 5, 2009 9.6 KB   SEATTLE, Oct. 5, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) today announced the appointment of Douglas E. Williams, Ph.D., Chief Executive Officer of ZymoGenetics, Inc. (Nasdaq: ZGEN), to its board of directors. "We are pleased to welcome Doug to our board of directors and look forward to the co... Read more Oncothyreon to present at BioCentury NewsMakers Conference Sep 10, 2009 9.6 KB   SEATTLE, Sep. 10, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 16th Annual BioCentury NewsMakers in the Biotech Industry Conference on Sept. 16, 2009 in New York. Dr. Kirkman will present at 3 p.m... Read more Oncothyreon to present at Rodman Renshaw Global Healthcare Conference Sep 3, 2009 9.2 KB   SEATTLE, WA, Sept 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman Renshaw 11th Annual Healthcare Conference taking place Sept. 9-11, 2009 in New York. Dr. Kirkman will present at 2 p.m... Read more Oncothyreon to present at Rodman & Renshaw Global Healthcare Conference Sep 3, 2009 9.8 KB   SEATTLE, WA, Sep. 3, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman & Renshaw 11th Annual Healthcare Conference taking place Sept. 9-11, 2009 in New York. Dr. Kirkman will present at 2 p.m. E... Read more Oncothyreon reports second quarter 2009 financial results Aug 12, 2009 18.3 KB   SEATTLE, Aug. 12, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008. O... Read more Oncothyreon announces closing of $15.0 million registered direct financing Aug 10, 2009 10.3 KB   SEATTLE, Aug. 10, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of approximately 2.28 million shares of its common stock and warrants to purchase approximately 684,000 shares of its common stock for gross proceeds of approximately $15.0 milli... Read more Oncothyreon announces webcast of second quarter 2009 financial results conference call Aug 6, 2009 9.6 KB   SEATTLE, Aug. 6, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its second quarter and year end 2009 financial results on Wednesday, August 1... Read more Oncothyreon announces commitments to purchase $15.0 million of company securities in a registered direct financing Aug 4, 2009 10.0 KB   SEATTLE, Aug. 4, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it has obtained commitments from several investors to purchase approximately 2.28 million shares of its common stock and warrants to purchase approximately 684,000 shares of its common stock for gross proceeds of approx... Read more Oncothyreon appoints Diana Hausman as Vice President of Clinical Development Aug 4, 2009 11.8 KB   SEATTLE, WA, Aug. 4, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced the appointment of Diana Hausman, M.D., as Vice President, Clinical Development at Oncothyreon. In this position, Dr. Hausman will be responsible for planning and implementing the clinical development prog... Read more Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer Aug 3, 2009 13.8 KB   SEATTLE, Aug. 3, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in San Francisco on August 1... Read more Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer Jun 22, 2009 13.7 KB   SEATTLE, Jun 22, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastati... Read more Oncothyreon appoints Scott Peterson as Vice President of Research and Development Jun 15, 2009 12.1 KB   SEATTLE, Jun 15, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced the appointment of Scott Peterson, Ph.D., as Vice President, Research and Development at Oncothyreon. In this position, Dr. Peterson will be responsible for overseeing those pre-clinical and non-clinical resea... Read more Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting May 30, 2009 17.0 KB   SEATTLE, WA, May 30, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that data from clinical trials for three of the Company's product candidates were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2009 in Orlando, Florida. The prese... Read more Oncothyreon announces closing of $11.1 million registered direct financing May 27, 2009 9.8 KB   SEATTLE, May 27, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of 3,878,993 shares of its common stock and warrants to purchase 2,909,244 shares of its common stock for gross proceeds of approximately $11.1 million on May 26, 2009. Oncothyreo... Read more Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing May 20, 2009 10.0 KB   SEATTLE, May 20, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it has obtained commitments from several investors to purchase approximately 3.88 million shares of its common stock and warrants to purchase approximately 2.91 million shares of its common stock for gross proceeds of a... Read more Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis May 18, 2009 12.9 KB   SEATTLE, May 18, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) today announced the presentation of data demonstrating the effectiveness of Oncothyreon's PX-866 in a preclinical model of pulmonary fibrosis. The data were presented earlier today by William D. Hardie, M.D., Associate Professor, Pulmonary ... Read more Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting May 18, 2009 12.2 KB   SEATTLE, May 18, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced upcoming presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, 2009 in Orlando, Florida. Abstracts related to our product candidates Stimuvax(R), PX-866 and PX-12 are now a... Read more Showing 1-20 of 159 Page: 1 2 3 ... 8  Next 20 = add release to Briefcase return to top ^